אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - everolimus, quantity: 7.5 mg - tablet - excipient ingredients: butylated hydroxytoluene; hypromellose; lactose monohydrate; lactose; crospovidone; magnesium stearate - the treatment of: - postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole and anastrozole - progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin - advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib - subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection - patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - everolimus, quantity: 5 mg - tablet - excipient ingredients: butylated hydroxytoluene; hypromellose; lactose monohydrate; lactose; crospovidone; magnesium stearate - the treatment of: - postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole and anastrozole - progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin - advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib - subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection - patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - everolimus, quantity: 2.5 mg - tablet - excipient ingredients: butylated hydroxytoluene; hypromellose; lactose monohydrate; lactose; crospovidone; magnesium stearate - the treatment of: - postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole and anastrozole - progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin - advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib - subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection - patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - everolimus -

ישראל - אנגלית - Ministry of Health

rafa laboratories ltd - diltiazem hydrochloride - capsules controlled release - diltiazem hydrochloride 120 mg - benzothiazepine derivatives - calcium channel blocker that is indicated for the treatment of hypertension and angina.

ישראל - אנגלית - Ministry of Health

rafa laboratories ltd - diltiazem hydrochloride - capsules controlled release - diltiazem hydrochloride 180 mg - benzothiazepine derivatives - calcium channel blocker that is indicated for the treatment of hypertension and angina.

ישראל - אנגלית - Ministry of Health

rafa laboratories ltd - diltiazem hydrochloride - capsules controlled release - diltiazem hydrochloride 240 mg - benzothiazepine derivatives - calcium channel blocker that is indicated for the treatment of hypertension and angina.

סינגפור - אנגלית - HSA (Health Sciences Authority)

viatris private limited - celecoxib - capsule - 400mg - celecoxib 400mg

סינגפור - אנגלית - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - imatinib mesylate 119.5 mg eqv imatinib base - tablet, film coated - 100 mg - imatinib mesylate 119.5 mg eqv imatinib base 100 mg

סינגפור - אנגלית - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - imatinib mesylate eqv imatinib base - tablet, film coated - 478.00 mg eqv. 400mg imatinib base - imatinib mesylate eqv imatinib base 400 mg